Literature DB >> 18027878

Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations.

Kenneth E Sherman1, Russell Fleischer, Katherine Laessig, Jeffrey Murray, William Tauber, Debra Birnkrant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18027878     DOI： 10.1002/hep.21985

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  HIV and liver disease forum: conference proceedings.

Authors:  Kenneth E Sherman; Marion Peters; Margaret James Koziel
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

Review 2.  Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline.

Authors:  Carrie L Jennings; Kenneth E Sherman
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

3.  Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis.

Authors:  Mohammed Mahmound Ahmed; Omar M E Abdel-Salam; Nadia A Mohammed; Dawoud Fakhry Habib; Hewida Ez-Eldin Gomaa
Journal:  EXCLI J       Date:  2013-07-02       Impact factor: 4.068
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.